|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Drug Interactions]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ===Drug Interactions===
| |
| | |
| Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5. Ticagrelor is also a p-glycoprotein (P-gp) substrate.
| |
| | |
| ===CYP3A inhibitors===
| |
| | |
| Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].
| |
| | |
| ===CYP3A inducers===
| |
| | |
| Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital) [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Aspirin===
| |
| | |
| Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA[see Warnings and Precautions (5.2) and Clinical Studies (14)].
| |
| | |
| Effect of BRILINTA on other drugs
| |
| | |
| Ticagrelor is an inhibitor of CYP3A4/5 and the P-glycoprotein transporter.
| |
| | |
| * Simvastatin, lovastatin
| |
| | |
| BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3)].
| |
| | |
| * Digoxin
| |
| | |
| Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy [see Clinical Pharmacology (12.3)].
| |
| | |
| * Other Concomitant Therapy
| |
| | |
| BRILINTA can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers. <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |